Advancement of Congressional rare disease drug approval policies
2026 · 3rd Quarter (July 1 - Sep 30)
IMMIX BIOPHARMA, INC.
Filed by FIRST PRINCIPLES STRATEGIES, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 20, 2026
- Income
- $20,000.00
- Expenses
- Not reported
- Registrant
- FIRST PRINCIPLES STRATEGIES, LLC
- Client
- IMMIX BIOPHARMA, INC.
- Filing UUID
- c6cdaafe-9198-4ccc-9f56-45f63de0b699
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.